44,320$
25,41%
Echtzeit-Aktienkurs GlaxoSmithkline PLC (Spons. ADRs)
Bid:
Ask:
Echtzeit-Chart der GlaxoSmithkline PLC (Spons. ADRs) Aktie
Börsenkurse GlaxoSmithkline PLC (Spons. ADRs)
Fundamentaldaten der GlaxoSmithkline PLC (Spons. ADRs) Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2021 [USD] | 46,92 Mrd. | 7,44 Mrd. | 6,03 Mrd. | 2,41 | 4,81% | 18,38 | 2,37 |
| 2020 [USD] | 43,73 Mrd. | 8,89 Mrd. | 7,37 Mrd. | 2,96 | 4,72% | 14,96 | 2,52 |
| 2019 [USD] | 43,06 Mrd. | 7,84 Mrd. | 5,93 Mrd. | 2,40 | 4,46% | 18,50 | 2,55 |
| 2018 [USD] | 41,10 Mrd. | 6,36 Mrd. | 4,83 Mrd. | 1,97 | 4,65% | 22,54 | 2,65 |
| 2017 [USD] | 38,87 Mrd. | 4,52 Mrd. | 1,97 Mrd. | 0,81 | 4,82% | 54,78 | 2,79 |
| 2016 [USD] | 37,53 Mrd. | 2,60 Mrd. | 1,23 Mrd. | 0,51 | 4,47% | 87,59 | 2,87 |
| 2015 [USD] | 36,55 Mrd. | 16,06 Mrd. | 12,87 Mrd. | 5,33 | 5,30% | 8,32 | 2,93 |
| 2014 [USD] | 37,88 Mrd. | 4,84 Mrd. | 4,54 Mrd. | 1,89 | 5,86% | 23,49 | 2,81 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der GlaxoSmithkline PLC (Spons. ADRs) Aktie
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.